The favorable toxicology data removes a key overhang and supports IND submission. Traders should watch for IND filing in Q4 2026 and potential partnership interest given the obesity market size. The stock has high binary risk given early-stage status.
Drug in focus
NMRA drug pipeline →NMRA-215
● Neutral Named in this press release- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 27 $1.66entry
- T+1 · 4mo ago +1.20%α +0.97% · $1.68
- T+5 · 4mo ago −3.01%α −4.09% · $1.61
- T+20 · 3mo ago −8.13%α −11.43% · $1.53
- T+60 · 28d ago −71.69%α −75.39% · $0.4700
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor for obesity and cardiometabolic disease. A repeat 13-week rat study showed no unexpected adverse findings, resolving concerns from a prior study where 5 of 142 animals had issues. The company plans to submit an IND in Q4 2026 and initiate a clinical study in 2026.
Key Facts
- Repeat 13-week rat toxicology study (n=162) showed no unexpected in-life adverse findings, resolving prior concerns from a study where 5 of 142 animals had issues.
- Company plans to submit an IND for NMRA-215 in Q4 2026 and initiate a clinical study in 2026.
- NMRA-215 demonstrated class-leading weight loss as monotherapy in a diet-induced obesity mouse model, additive weight loss with semaglutide, and improved peripheral cardiometabolic biomarkers.
- NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor targeting obesity and cardiometabolic disorders.
Financial Impact
Pre-clinical data de-risks NMRA-215, a potential blockbuster obesity asset. No financial figures disclosed.
Risk Factors
- Histopathology report for the 3-month toxicity study is still pending, which could reveal new issues.
- Pre-clinical efficacy may not translate to humans; clinical trial risks remain high.
- Company is clinical-stage with no approved products; capital needs may require future dilution.
- Competition from GLP-1 drugs (semaglutide, tirzepatide) and other NLRP3 inhibitors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333375 |
Track record
14 reports on NMRA
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
- Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
- Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
- Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
- Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 4/10 No price data
- Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
- Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
- Jul 27, 202616w ago Press Release Bullish 7/10 Viewing Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers